Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (41-50 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology (Oxford, England)|December 15, 2012
Should we be morbid about comorbidities in the rheumatic diseases?Dirk Elewaut, Nicola Goodson, Roy Fleischmann
Expert Opinion on Pharmacotherapy|October 22, 2002
MeloxicamRoy Fleischmann, Imran Iqbal, Gleb Slobodin
Rheumatology (Oxford, England)|October 17, 2012
Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trialRoy Fleischmann, Arthur Kavanaugh, Joseph Smolen
Expert Opinion on Pharmacotherapy|December 24, 2005
Tacrolimus in rheumatoid arthritisRoy Fleischmann, Imran Iqbal, Richard L Stern
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
Arthritis Research & Therapy|July 2, 2004
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?Sergio Schwartzman, Roy Fleischmann, G James Morgan
RMD Open|September 1, 2018
Distinguishing rheumatoid arthritis from psoriatic arthritisJoseph F Merola, Luis R Espinoza, Roy Fleischmann
Drug Safety|April 12, 2002
Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanerceptRoy Fleischmann, Imran Iqbal, Pallavi Nandeshwar, et al.
Annals of the Rheumatic Diseases|June 12, 2026
Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et alRoy Fleischmann, Orsolya Nagy, Jingchen Ren, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 20, 2016
ReplyRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Pageof 19

Showing results (41-50 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|December 15, 2012
Should we be morbid about comorbidities in the rheumatic diseases?Dirk Elewaut, Nicola Goodson, Roy Fleischmann
Expert Opinion on Pharmacotherapy|October 22, 2002
MeloxicamRoy Fleischmann, Imran Iqbal, Gleb Slobodin
Rheumatology (Oxford, England)|October 17, 2012
Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trialRoy Fleischmann, Arthur Kavanaugh, Joseph Smolen
Expert Opinion on Pharmacotherapy|December 24, 2005
Tacrolimus in rheumatoid arthritisRoy Fleischmann, Imran Iqbal, Richard L Stern
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
Arthritis Research & Therapy|July 2, 2004
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?Sergio Schwartzman, Roy Fleischmann, G James Morgan
RMD Open|September 1, 2018
Distinguishing rheumatoid arthritis from psoriatic arthritisJoseph F Merola, Luis R Espinoza, Roy Fleischmann
Drug Safety|April 12, 2002
Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanerceptRoy Fleischmann, Imran Iqbal, Pallavi Nandeshwar, et al.
Annals of the Rheumatic Diseases|June 12, 2026
Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et alRoy Fleischmann, Orsolya Nagy, Jingchen Ren, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 20, 2016
ReplyRoy Fleischmann, Sean E Connolly, Michael A Maldonado, et al.
Pageof 19